Treatment of the Osgood Schlatter (OSGOOD)

August 11, 2020 updated by: Hospices Civils de Lyon

Treatment of the Osgood Schlatter Disease by Immobilization ( Ankle Cruro Resin ) Versus Sporting Rest ( Reference Treatment ) : Randomized Controlled Study

The disease Osgood-Schlatter is most commonly found in sports teenager growing up apophysose accounting for 28.4% of osteochondrosis by Breck. It relates to 62% of osteochondrosis knee and affects adolescent girls between 10 and 12 and boys between 12 and 15 It is usually considered a benign pathology that cures in the majority of cases. However, in 5-10% of cases there is persistent residual pain in adulthood.

The classic complication is the avulsion fracture of the tibial tuberosity in adolescents who continued his sports without restriction.

The possible consequences are numerous including the presence of a free bone fragment at the insertion of the tendon originally described by Osgood the establishment of a genu recurvatum, a high kneecap or patella alta and an enlarged tibial tuberosity (ATT) annoying sport.

The main two treatments are complete rest from sport activity or cast immobilization.

The main objective is to compare these two technics according to the proportion of full sporting recovering at 12 months

Study Overview

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lyon, France, 69003
        • Department of Sport's medicine, Hospital Edouard Herriot- Hospices Civils de Lyon, 5 Place d'Arsonval

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

9 years to 15 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Boys and girls
  • From 9 to 15 years old
  • Coming to consult in the Sports' medicine ward
  • Patients diagnosed with Osgood-Schlatter disease defined by a swelling of the anterior tibial tuberosity (ATT) , pain on palpation of the ATT , pain with passive knee flexion , pain thwarted knee extension and soft rays in profile knee radiography according to the classification of Woolfrey and Chandler (types A -C
  • Unilateral or bilateral
  • Previously treated or not
  • Agreed to participate
  • Agreement of the parents to participate
  • Affiliation to national security

Exclusion Criteria:

  • Contraindication to the set-up of vascular access in femoral position (femoral Scarpa wound, aortic dissection)
  • Local infection
  • Hypothermia <32°C
  • Need for implementation of arterial catheter only
  • Need for implementation of venous catheter only

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cast immobilization
36 patients in the experimental cast immobilization
Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
Active Comparator: complete sport rest
36 patients in the complete sport rest group
Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Restarting a sporting activity
Time Frame: 12 weeks after intervention
Comparison between the 2 groups of the proportion of patient returning to sports activity 12 weeks after treatment.
12 weeks after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anterior tibial tuberosity pain
Time Frame: Inclusion visit Day 0
Mean pain evaluation using Visual analogic scale between the 2 groups, at Anterior tibial tuberosity palpation
Inclusion visit Day 0
Anterior tibial tuberosity pain
Time Frame: follow-up visit week 4
Mean pain evaluation using Visual analogic scale between the 2 groups, at Anterior tibial tuberosity palpation
follow-up visit week 4
Anterior tibial tuberosity pain
Time Frame: follow-up visit week 8
Mean pain evaluation using Visual analogic scale between the 2 groups, at Anterior tibial tuberosity palpation
follow-up visit week 8
Anterior tibial tuberosity pain
Time Frame: follow-up visit week 12
Mean pain evaluation using Visual analogic scale between the 2 groups, at Anterior tibial tuberosity palpation
follow-up visit week 12
Pain killer consumption
Time Frame: follow-up visit week 4
Evaluation of pain killer consumption (type, dose ,frequency) between the 2 groups
follow-up visit week 4
Pain killer consumption
Time Frame: follow-up visit week 8
Evaluation of pain killer consumption (type, dose ,frequency) between the 2 groups
follow-up visit week 8
Quality of life assessment
Time Frame: inclusion visit Day 0
Quality of life will be assessed using the SF-12 auto questionnaire
inclusion visit Day 0
Quality of life assessment
Time Frame: follow-up visit week 12
Quality of life will be assessed using the SF-12 auto questionnaire
follow-up visit week 12
Quality of life assessment
Time Frame: follow-up visit month 6
Quality of life will be assessed using the SF-12 auto questionnaire. As the standard follow-up visit are over, this questionnaire will be asked by phone
follow-up visit month 6
Activity level assessment
Time Frame: inclusion visit Day 0
Activity level will be assessed using the Tegner scale
inclusion visit Day 0
Activity level assessment
Time Frame: follow-up visit week 12
Activity level will be assessed using the Tegner scale
follow-up visit week 12
Activity level assessment
Time Frame: follow-up visit month 6
Activity level will be assessed using the Tegner scale. As the standard follow-up visit are over, this scale will be asked by phone
follow-up visit month 6
complete sport rest compliance assessment
Time Frame: follow-up visit week 4
The complete sport rest compliance will be assessed using a visual analogic scale (0 to 10, 0 will be a complete rest compliance)
follow-up visit week 4
painfulness due to immobilization cast
Time Frame: follow-up visit week 12
The patient in the cast immobilization group will be asked what was the level his/her level of cast tolerance: bad, average, good or very good.
follow-up visit week 12
Quadricipital shortness
Time Frame: inclusion visit Day 0
The Quadricipital shortness will be evaluated thanks to the knee flexion angle will be measured using the modified Thomas test as well as hamstring muscles length measured using the popliteal angle
inclusion visit Day 0
Quadricipital shortness
Time Frame: follow-up visit week 4
The Quadricipital shortness will be evaluated thanks to the knee flexion angle will be measured using the modified Thomas test as well as hamstring muscles length measured using the popliteal angle
follow-up visit week 4
Quadricipital shortness
Time Frame: follow-up visit week 8
The Quadricipital shortness will be evaluated thanks to the knee flexion angle will be measured using the modified Thomas test as well as hamstring muscles length measured using the popliteal angle
follow-up visit week 8
Patella size
Time Frame: inclusion visit Day 0
The patella size will be measure on the lateral radiograph using the Caton and Deschamp index
inclusion visit Day 0
Patella size
Time Frame: follow-up visit week 8
The patella size will be measure on the lateral radiograph using the Caton and Deschamp index
follow-up visit week 8
Radiographic evolution of Osgood Schlatter disease
Time Frame: follow-up visit week 12
Both clinicians and radiologist will evaluate separately the evolution of Osgood Schlatter disease using a new classification. It is based on 3 parameters: anterior tibial tuberosity fragmentation, thickening of soft tissues and presence or not of an ossicle.
follow-up visit week 12
Potential return to sport activity
Time Frame: follow visit week 8
After a week of training, patients of each group will be evaluated and the clinician will consider the possibility of a potential return to sport activity the week 8 of follow-up
follow visit week 8
Return to sport activity at the initial level
Time Frame: follow visit month 6
Six months after the intervention, patients will be called to evaluate if they were able to return to a sport activity at the same level they were before the disease. This proportion will be compared in between both groups
follow visit month 6
alternative options during the study
Time Frame: follow visit month 6
Each patient will be ask during the phone interview at 6 months if the consulted another physicians or if they used an alternative to that proposed in our study.
follow visit month 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jean-Francois LUCCIANI, MD, Department of Sport's medicine, Hospital Edouard Herriot- Hospices Civils de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2015

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

June 29, 2016

First Submitted That Met QC Criteria

July 1, 2016

First Posted (Estimate)

July 6, 2016

Study Record Updates

Last Update Posted (Actual)

August 13, 2020

Last Update Submitted That Met QC Criteria

August 11, 2020

Last Verified

August 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 69HCL16_0404

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osgood Schlatter Disease

Clinical Trials on cast immobilization group

3
Subscribe